Divalproex Sodium
Product Images NDC 68071-2717

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68071-2717). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Pdp (68071 2717 6)

Pdp (68071 2717 6)
Divalproex Sodium 250mg tablets label from NuCare Pharmaceuticals, Inc. The label indicates a supply of 60 delayed-release tablets. Tablets are oval-shaped, peach colored, and imprinted with "D85" on one side. Packaging includes dosing instructions and storage conditions, with warnings to keep out of reach of children and recommended storage temperature between 68-77°F.*
FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
Bar chart comparing percentage values between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) in two studies. Study 1 (YMRS) shows 26% for PBO and 60% for DVPX, while Study 2 (MRS) shows 29% for PBO and 58% for DVPX. The chart includes a note indicating statistical significance (p < 0.05).*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
A line graph comparing the percent reduction in CPS rate between Divalproex Sodium delayed-release tablets and placebo across percentages of patients. The vertical axis ranges from -100% (worsening) to 100% (improvement), with a horizontal line indicating no change. The Divalproex Sodium line shows a greater improvement compared to placebo over the patient population percentiles.*
FDA Label Image

Figure 3 (Divalproex Fig3)

Figure 3 (Divalproex Fig3)
A line graph titled Figure 3 depicting the percentage reduction in CRS rate on the vertical axis and percentage of patients on the horizontal axis. Two lines represent high dose (solid line) and low dose (dashed line) treatments, showing trends of improvement or worsening in patients receiving Divalproex Sodium.*
FDA Label Image

Figure 4 (Divalproex Fig4)

Figure 4 (Divalproex Fig4)
A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' showing mean migraine rates for placebo and divalproex sodium delayed-release tablets across two studies. The chart compares migraine rates between placebo and divalproex sodium groups, with notes indicating dosages used in each study.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)
Chemical structure diagram of Divalproex Sodium showing its molecular composition and arrangement, including sodium ions and carbon, hydrogen, and oxygen atoms, represented with chemical bonds and molecular groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.